These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 24237448)

  • 1. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
    Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
    Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide and T-cell homeostasis: tolerating immune reconstitution after autologous stem cell transplant.
    Perry C; Polliack A
    Leuk Lymphoma; 2014 Aug; 55(8):1699-700. PubMed ID: 24410588
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA; Becker PS; Bensinger W
    Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
    Biran N; Jacobus S; Vesole DH; Callander NS; Fonseca R; Williams ME; Abonour R; Katz MS; Rajkumar SV; Greipp PR; Siegel DS
    Blood Cancer J; 2016 Sep; 6(9):e466. PubMed ID: 27588519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommend maintenance therapy with lenalidomide in multiple myeloma.
    Manasanch EE
    Semin Oncol; 2016 Dec; 43(6):712-713. PubMed ID: 28061994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
    Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
    Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
    Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
    Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
    Al-Ani F; Louzada M
    Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
    McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
    J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk adapted post-transplant maintenance in multiple myeloma.
    Vaxman I; Gertz M
    Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.